Ginkgo Automation Appoints Brian O'Sullivan as Head of Commercial to Accelerate External Growth
Ginkgo Bioworks (NYSE: DNA) has appointed Brian O'Sullivan as Head of Commercial for Ginkgo Automation to accelerate external growth. O'Sullivan, formerly from HighRes Biosolutions, will oversee all revenue-generating functions including sales, business development, and marketing.
The appointment comes as Ginkgo Automation expands from internal R&D support to serving external clients with its RAC (Reconfigurable Automation Cart) hardware, Catalyst scheduling software, and remote monitoring services. O'Sullivan brings extensive experience in commercial leadership, having successfully grown HighRes's operations globally and held senior positions at Agilent Technologies, Velocity11, and Beckman Coulter.
Ginkgo Bioworks (NYSE: DNA) ha nominato Brian O'Sullivan responsabile commerciale di Ginkgo Automation per accelerare la crescita verso clienti esterni. O'Sullivan, proveniente da HighRes Biosolutions, supervisionerà tutte le funzioni legate ai ricavi, incluse vendite, sviluppo commerciale e marketing.
La nomina arriva mentre Ginkgo Automation si espande dal supporto interno alla R&S all'offerta a clienti esterni del suo hardware RAC (Reconfigurable Automation Cart), del software di pianificazione Catalyst e dei servizi di monitoraggio remoto. O'Sullivan porta un'ampia esperienza nella leadership commerciale: ha sviluppato con successo le attività di HighRes a livello globale e ha ricoperto ruoli dirigenziali in Agilent Technologies, Velocity11 e Beckman Coulter.
Ginkgo Bioworks (NYSE: DNA) ha nombrado a Brian O'Sullivan como Responsable Comercial de Ginkgo Automation para acelerar el crecimiento externo. O'Sullivan, procedente de HighRes Biosolutions, supervisará todas las funciones generadoras de ingresos, incluidas ventas, desarrollo de negocio y marketing.
El nombramiento se produce mientras Ginkgo Automation pasa del apoyo interno a I+D a atender a clientes externos con su hardware RAC (Reconfigurable Automation Cart), el software de programación Catalyst y servicios de monitorización remota. O'Sullivan aporta una amplia experiencia en liderazgo comercial: ha impulsado con éxito la expansión global de HighRes y ha ocupado cargos directivos en Agilent Technologies, Velocity11 y Beckman Coulter.
Ginkgo Bioworks (NYSE: DNA)는 외부 성장 가속화를 위해 Brian O'Sullivan을 Ginkgo Automation의 영업 책임자(Head of Commercial)로 임명했다. 이전에 HighRes Biosolutions에 재직한 O'Sullivan은 영업, 사업개발, 마케팅 등 수익 창출 관련 모든 기능을 총괄한다.
이번 임명은 Ginkgo Automation이 내부 연구개발 지원에서 벗어나 자체 RAC (Reconfigurable Automation Cart) 하드웨어, 일정 관리 소프트웨어 Catalyst 및 원격 모니터링 서비스로 외부 고객을 대상으로 사업을 확장하는 시점에 이루어졌다. O'Sullivan은 상업적 리더십 경험이 풍부하며 HighRes의 글로벌 사업을 성공적으로 확대했고 Agilent Technologies, Velocity11, Beckman Coulter에서 고위직을 역임했다.
Ginkgo Bioworks (NYSE: DNA) a nommé Brian O'Sullivan au poste de responsable commercial de Ginkgo Automation afin d'accélérer sa croissance externe. O'Sullivan, anciennement chez HighRes Biosolutions, supervisera toutes les fonctions génératrices de revenus, notamment les ventes, le développement commercial et le marketing.
Cette nomination intervient alors que Ginkgo Automation étend son offre, passant du soutien interne à la R&D à la prise en charge de clients externes avec son matériel RAC (Reconfigurable Automation Cart), le logiciel de planification Catalyst et des services de surveillance à distance. O'Sullivan apporte une vaste expérience en direction commerciale : il a développé avec succès les activités de HighRes à l'international et a occupé des postes de direction chez Agilent Technologies, Velocity11 et Beckman Coulter.
Ginkgo Bioworks (NYSE: DNA) hat Brian O'Sullivan zum Leiter des Commercial-Bereichs von Ginkgo Automation ernannt, um das externe Wachstum zu beschleunigen. O'Sullivan, zuvor bei HighRes Biosolutions, wird alle umsatzgenerierenden Funktionen beaufsichtigen, einschließlich Vertrieb, Geschäftsentwicklung und Marketing.
Die Ernennung erfolgt, während Ginkgo Automation sich von der internen F&E-Unterstützung hin zu Dienstleistungen für externe Kunden mit seiner RAC (Reconfigurable Automation Cart)-Hardware, der Planungssoftware Catalyst und Fernüberwachungsdiensten erweitert. O'Sullivan bringt umfangreiche Erfahrung in kommerzieller Führung mit: Er hat die Aktivitäten von HighRes weltweit erfolgreich ausgebaut und leitende Positionen bei Agilent Technologies, Velocity11 und Beckman Coulter bekleidet.
- Strategic expansion from internal R&D to external client services
- Appointment of experienced commercial leader with proven track record in scaling operations globally
- Development of comprehensive automation solution combining hardware and AI-ready software
- None.
Seasoned life‑science executive to spearhead global go‑to‑market strategy as Ginkgo Automation scales external sales across biopharma, techbio, and new science‑driven markets while continuing to support internal programs.
In his new role, Brian will oversee all revenue‑generating functions, including sales, business development, channel partnerships, marketing, and customer success, at a pivotal moment for Ginkgo Automation. Over the past year, the business unit has quickly evolved from supporting Ginkgo's internal R&D to providing its modular RAC (Reconfigurable Automation Cart) hardware, Catalyst scheduling and orchestration software, and remote monitoring and error resolution services to external clients. Ginkgo Automation now serves a rapidly expanding customer base across biopharma, diagnostics, and national laboratories.
"Brian has consistently built top-performing commercial teams that translate advanced technology into clear customer value," said Will Serber, GM, Ginkgo Automation. "His expertise in developing and executing capex and software solutions, executing large automation transactions, and his robust network across the life sciences market uniquely positions us to scale globally and maximize the power of our platform."
At HighRes, Brian built the commercial organization from the ground up, dramatically grew annual bookings, established key strategic alliances across leading industry segments, and spearheaded the company's expansion into
"Ginkgo Automation pairs best‑in‑class hardware in a novel design with an AI‑ready software stack that closes the loop between experiment design and data generation – exactly what scientists need to accelerate discovery," said Brian O'Sullivan. "I'm thrilled to join this talented team and empower customers to reimagine what's possible in their labs."
Brian will be based in
Ginkgo Automation capabilities can now be deployed at your site. Find out more about our RACs and Catalyst automation software here or at automation.ginkgo.bio
GINKGO BIOWORKS INVESTOR CONTACT:
investors@ginkgobioworks.com
GINKGO BIOWORKS MEDIA CONTACT:
press@ginkgobioworks.com
About Ginkgo Bioworks
Ginkgo Bioworks builds the tools that make biology easier to engineer for everyone. Ginkgo R&D Solutions delivers customizable R&D packages—such as protein engineering, nucleic acid design, and cell-free systems—giving partners a comprehensive way to accelerate innovation across therapeutics, diagnostics, & manufacturing. Ginkgo Automation sells modular, integrated laboratory automation so scientists can spend their days planning and analyzing experiments rather than pipetting in the lab. Ginkgo Datapoints uses Ginkgo's in-house automation to generate the large lab data sets to power your AI models. Ginkgo Biosecurity is building and deploying the next-generation infrastructure and technologies that global leaders need to predict, detect, and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and ginkgobiosecurity.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.
Forward-Looking Statements of Ginkgo Bioworks
This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of Ginkgo's cell programming platform. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to realize near-term and long-term cost savings associated with our site consolidation plans, including the ability to terminate leases or find sub-lease tenants for unused facilities, (ii) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vii) the outcome of any pending or potential legal proceedings against Ginkgo, (viii) our ability to realize the expected benefits from and the success of our Foundry platform programs and Codebase assets, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, (x) the product development, production or manufacturing success of our customers, (xi) our exposure to the volatility and liquidity risks inherent in holding equity interests in other operating companies and other non-cash consideration we may receive for our services, (xii) the potential negative impact on our business of our restructuring or the failure to realize the anticipated savings associated therewith and (xiii) the uncertainty regarding government budgetary priorities and funding allocated to government agencies. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the
GINKGO BIOWORKS INVESTOR CONTACT:
investors@ginkgobioworks.com
GINKGO BIOWORKS MEDIA CONTACT:
press@ginkgobioworks.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-automation-appoints-brian-osullivan-as-head-of-commercial-to-accelerate-external-growth-302527500.html
SOURCE Ginkgo Bioworks
FAQ
Who is the new Head of Commercial at Ginkgo Automation (NYSE: DNA)?
What are the main products offered by Ginkgo Automation?
What markets does Ginkgo Automation (DNA) serve?
What are Brian O'Sullivan's immediate priorities at Ginkgo Automation?
What is Brian O'Sullivan's background and experience?
